Valuation: GENinCode Plc

Market Cap 6.02M 8M 7.03M 6.56M 11.28M 767M 11.56M 77.84M 30.44M 379M 30.05M 29.4M 1.31B P/E 2026 *
-1.14x
P/E 2027 * -
Enterprise Value 5.22M 6.94M 6.1M 5.69M 9.78M 665M 10.02M 67.5M 26.4M 329M 26.06M 25.49M 1.14B EV / Sales 2026 *
1.1x
EV / Sales 2027 * -
Free-Float
59.68%
Yield 2026 *
-
Yield 2027 * -
1 day-4.25%
1 week-12.46%
Current month-17.63%
1 month-17.63%
3 months-36.17%
6 months-35.63%
Current year-68.08%
1 week 0.76
Extreme 0.76
0.9
1 month 0.75
Extreme 0.75
1
Current year 0.75
Extreme 0.75
2.5
1 year 0.75
Extreme 0.75
5.5
3 years 0.75
Extreme 0.75
14
5 years 0.75
Extreme 0.75
47
10 years 0.75
Extreme 0.75
48
Manager TitleAgeSince
Chief Operating Officer 51 06/09/2018
Chief Executive Officer 62 06/09/2018
Director of Finance/CFO 57 01/11/2020
Director TitleAgeSince
Chairman 62 06/09/2018
Director/Board Member 51 06/09/2018
Director/Board Member 65 01/05/2020
Date Insider Type Main position Quantity % Market Cap.
06/05/26 Free

Chief Financial Officer

13,523,757 1.7959%
06/05/26 Free

Founder

30,428,453 4.0407%
06/05/26 Free

Director

1,267,852 0.1684%
Change 5-day change 1-year change 3-year change Capi.($)
-4.25%-12.46%-57.44%-93.40% 8M
+0.31%-4.43%+232.57%+271.12% 19.1B
-1.03%+4.42%-42.22%-26.15% 9.78B
-2.57%-4.41%+38.50%+13.70% 6.51B
-1.55%-1.55%+230.86%-26.37% 5.88B
+0.31%-1.32%-14.84%-20.65% 5.55B
0.00%+1.37%-43.35% - 4.41B
-1.67%+4.28%-20.94%-31.72% 4.27B
-0.33%-18.17%+71.57%+88.36% 4.14B
+2.54%0.00%-18.78%-43.19% 2.76B
Average -0.83%-0.61%+37.59%+14.63% 6.24B
Weighted average by Cap. -0.49%-1.30%+88.44%+83.68%

Financials

2026 *2027 *
Net sales 4.73M 6.29M 5.52M 5.16M 8.86M 602M 9.08M 61.14M 23.91M 298M 23.6M 23.09M 1.03B -
Net income -5.02M -6.67M -5.86M -5.47M -9.4M -639M -9.63M -64.85M -25.36M -316M -25.03M -24.49M -1.09B -
Net Debt -800K -1.06M -934K -872K -1.5M -102M -1.53M -10.34M -4.04M -50.37M -3.99M -3.9M -174M -
Logo GENinCode Plc
GENinCode Plc is a United Kingdom-based predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer. The Company operates business units in the United Kingdom, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc. Its predictive technology provides patients and physicians with preventive care and treatment strategies. GENinCode invitro-diagnostic molecular tests combine clinical algorithms and AI bioinformatics to advance patient risk assessment to prevent the onset of cardiovascular disease and ovarian cancer. Its testing products include CARDIO inCode Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA Test. Its SITAB is an online Web portal, which provides health care practitioners with a systemized approach to request, record, process and report their clinical and genetic test results. Its CARDIO inCode Score is a genetic test for the evaluation of the coronary genetic load based on a polygenic risk score.
Employees
44
Date Price Change Volume
30/07/26 GBX 0.7660 -4.25% 244,975
29/07/26 GBX 0.8000 -3.03% 1,432,400
28/07/26 GBX 0.8250 0.00% 2,878,135
27/07/26 GBX 0.8250 +3.13% 512,054
24/07/26 GBX 0.8000 -8.57% 3,159,585
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.008000GBP
Average target price
0.0750GBP
Spread / Average Target
+837.50%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GENI Stock